MedTrace Logo

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

NCT01463059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2013-03-25

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy and safety of CDP6038 administered subcutaneous (sc) at various doses compared to placebo.

Conditions

Interventions

BIOLOGICAL

Placebo

Placebo solution for injection, administered as subcutaneous injections

BIOLOGICAL

Olokizumab 60 mg

Olokizumab 60 mg solution for injection, administered as subcutaneous injections

BIOLOGICAL

Olokizumab 120 mg

Olokizumab 120 mg solution for injection, administered as subcutaneous injections

BIOLOGICAL

Olokizumab 240 mg

Olokizumab 240 mg solution for injection, administered as subcutaneous injections

Sponsors & Collaborators

  • UCB Japan Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Japan
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01463059 on ClinicalTrials.gov